Pharmacokinetic and pharmacodynamic interaction between irbesartan and hydrochlorothiazide in renal hypertensive dogs

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 6, 2005, Pages 863-869

  Huang, Xiao Hui ^a   Qiu, Fu Rong ^b   Xie, Hai Tang ^c   Li, Jun ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b WANNAN MEDICAL COLLEGE   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Drug interaction; Hydrochlorothiazide; Irbesartan; Pharmacodynamics; Pharmacokinetics

Indexed keywords

HYDROCHLOROTHIAZIDE; IRBESARTAN; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG POTENTIATION; FEMALE; HYSTERESIS; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MULTIPLE DRUG DOSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; SINGLE DRUG DOSE; STEADY STATE; ANIMAL; BIOLOGICAL MODEL; DRUG COMBINATION; DRUG INTERACTION;

ANIMALS; BIPHENYL COMPOUNDS; DOGS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HYDROCHLOROTHIAZIDE; HYPERTENSION, RENAL; MODELS, BIOLOGICAL; TETRAZOLES;

EID: 33644663217     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000191289.35182.7e     Document Type: Article

References (24)

1. Kaplan NM. Implications for cost-effectiveness. Combination therapy for systemic hypertension. Am J Cardiol. 1995;76:595-597.
2. Waeber B, Brunner HR. Main objectives and new aspects of combination treatment of hypertension. J Hypertens. 1995;13(Suppl):S15-S19.
3. Waeber B. A review of irbesartan in antihypertensive therapy: comparison with other antihypertensive agents. Curr Ther Res. 2001;62:505-521.
4. Greathouse M. A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations? Congest Heart Fail. 2002;8:313-320.
5. Rosenstock J, Rossi L, Lin CS, et al. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. J Clin Pharm Ther. 1998;23:433-440.
6. Mancia G. Clinical differences among angiotensin II receptor antagonists. Blood Press Suppl. 2001;2:19-24.
7. Mao GG, Chen B, Sun H, et al. Relative bioavailability of irbesartan capsules in healthy volunteers. Chin J Clin Pharmacol. 2001;17:207-209.
8. Vachharajani NN, Shyu WC, Chando TJ, et al. Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. J Clin Pharmacol. 1998;38:702-707.
9. Ismail Z, Triggs EJ, Smithurst BA, et al. The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. Eur J Clin Pharmacol. 1989;37:167-171.
10. Davi H, Tronquet G, Miscoria L, et al. Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques. Drug Metab Dispos. 2000;28:79-88.
11. Graham D, Hamilton C, Beattie E, et al. Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences. J Hypertens. 2004;22:329-337.
12. Brosnan MJ, Hamilton CA, Graham D, et al. Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. J Hypertens. 2002;20:281-286.
13. Derendorf H, Lesko LJ, Chaikin P, et al. Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol. 2000;40:1399-1418.
14. Derendorf H, Meibohm B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm Res. 1999;16:176-177.
15. Xu SY, Bian RL, Chen X. Animal Models of Hypertension. The Methodology of Pharmacological Experiment. 3rd ed. Beijing: People's Sanitation Press; 2002:950-951.
16. Collurn WA. Simultaneous pharmacokinetics and pharmacodynamics modeling. J Pharmacokinet Biopharm. 1981;9:367-388.
17. Yin XX, Zhang YD, Luo JP. Pharmacokinetic pharmacodynamic modeling of metoprolol stereoisomers in spontaneously hypertensive rat. Acta Pharmacol Sin. 1997;18:104-108.
18. Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther. 1997;35:401-413.
19. Chen ZY, Zheng QS, Sun RY. Introduction to the main functions of DAS pharmacological software. Chin J Clin Pharmacol Ther. 2002;7:562-564.
20. McCrea JB, Lo M-W, Tomasko L, et al. Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide. J Clin Pharmacol. 1995;35:1200-1206.
21. Beerman B, Groschinsky-Grind M, Rosen A. Absorption, metabolism, and excretion of hydrochlorothiazide. Clin Pharmacol Ther. 1976;19:531-537.
22. McCrea JB, Lo M-W, Tomasko L, et al. Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide. J Clin Pharmacol. 1995;35:1200-1206.
23. Weisser K, Schloos J, Jakob S, et al. The influence of hydrochlorothiazide on the pharmacokinetics of enalapril in elderly patients. Eur J Clin Pharmacol. 1992;43:173-177.
24. Nilsen OG, Sellevold OFM, Romfo OS, et al. Pharmacokinetics and effects on renal function following cilazapril and hydrochlorothiazide alone and in combination in healthy subjects and hypertensive patients. Br J Clin Pharmacol. 1989;27:323S-328S.